These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37526182)

  • 1. Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration.
    Woods RH
    Curr Drug Saf; 2024; 19(2):261-267. PubMed ID: 37526182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual/Buccal buprenorphine and dental problems: a pharmacovigilance study.
    Barus R; Montastruc F; de Canecaude C; Bagheri H; Sommet A; Lapeyre-Mestre M
    Expert Opin Drug Saf; 2023; 22(12):1283-1287. PubMed ID: 37584264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
    Woods RH
    Br J Clin Pharmacol; 2023 Aug; 89(8):2386-2395. PubMed ID: 36321844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
    Kwan ATH; Rosenblat JD; Mansur RB; Teopiz KM; McIntyre RS
    J Affect Disord; 2024 Sep; 360():421-426. PubMed ID: 38795777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
    Jiang A; Wei C; Zhu W; Wu F; Wu B
    Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
    Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
    Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS).
    Zhou Y; Xie W; Zheng C; Liu L; Chen Z; Wang X
    Clin Endocrinol (Oxf); 2022 May; 96(5):690-697. PubMed ID: 34913180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
    Ke C; Chen M; Huang Y; Chen Y; Lin C; Huang P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5253-5264. PubMed ID: 38270617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
    Ohyama K; Kawakami H; Inoue M
    Biol Pharm Bull; 2017; 40(5):616-620. PubMed ID: 28458346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
    Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
    Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.
    Chinzowu T; Chyou TY; Nishtala PS
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1190-1198. PubMed ID: 35670078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.